The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

TARS FINANCIAL STATEMENTS

Tarsus Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

TARSTarsus Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
0250 M500 M202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue606.3 M $Gross Profit549.3 M $ · 91%Operating Income-48.5 M $ · -8%Pre-tax Income-44.1 M $ · -7%Net Income to Owners-46.5 M $ · -8%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue606.3 M $+105.2%
Gross Profit549.3 M $+99.1%
Operating Income-48.5 M $—
EBITDA-35.2 M $—
Net Income to Owners-46.5 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0200 M400 M600 M202120222023202420252026

Capital Structure

Q2 2026
Total Assets611.1 M
  • Equity346.7 M $57%
  • Current Liabilities175.8 M $29%
  • Long-term Liabilities88.7 M $15%

Key Figures

YoY change
Total Assets611.1 M $+23.5%
Total Liabilities264.4 M $+62.8%
Total Equity346.7 M $+4.2%
Cash & ST Investments449.7 M $+18.0%
Total Debt——
Net Debt-204.6 M $—

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-100 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
050 M100 M79.7 M $Operating23.8 M $Investing9.6 M $Financing113.2 M $Net Change

Key Figures

YoY change
Operating Cash Flow79.7 M $—
Capital Expenditures18.2 M $+161.4%
Free Cash Flow61.5 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on TARS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 2, 26. This content is for informational purposes only and is not investment advice.